T2 Biosystems brought on two former Hologic executives to help it ramp up for the commercial rollout of its T2Candida rapid diagnostic assay.
Diagnostics giant LabCorp is betting sluggish demand and uncertain reimbursement will step all over its 2014 revenue, an announcement that sent the company's shares down nearly 10% in premarket trading.
Starting this January, FierceBiomarkers is merging with its sister publication, FierceDiagnostics. FierceDiagnostics will retain its name and brand, but coverage will expand to include the use of biomarkers as they relate to the broader diagnostics industry.
Quest Diagnostics plans to debut its new BRCA-related cancer predictive test at a major medical conference this week, doing anything but keeping a low profile in the wake of rival Myriad Genetics' patent infringement lawsuit.
On the way in the door as the new CEO of Hologic, Stephen MacMillan said he would oversee further growth of the women's diagnostic medical imaging and surgical products company, despite Hologic's recent efforts to reorganize.
Irish medical device giant Covidien over the weekend announced a definitive agreement to acquire PillCam maker Given Imaging for $860 million, ending about a year of takeover talk.
The FDA backs a market that lets consumers easily gain information about their genomes and genetic risks, an agency official said, despite its move to stop 23andMe from selling its direct-to-consumer health-related genetic tests until they obtain formal regulatory approval.
Boston Children's Hospital spinout Claritas Genomics, a genetic diagnostic testing company, attracted an investment from IT specialist Cerner, and the two will collaborate to develop a computing infrastructure designed to smooth the diagnostic process from start to finish.
Switzerland's Biocartis will link up with Belgium's VIB research institute to develop a diagnostic test useful for colorectal and other cancers, the company said.
Amid scorn and scrutiny from the FDA, 23andMe is facing a class-action lawsuit claiming the company misled customers in selling genetic tests with no real scientific value, and plaintiffs want at least $5 million in damages.